Transurethral microwave thermotherapy: From evidence-based medicine to clinical practice

Current Opinion in Urology

Volumn 17, Issue 1, 2007, Pages 12-16

  Gravas, Stavros ^a   Melekos, Michael D ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Benign prostatic obstruction; Clinical guidelines; Evidence based medicine; Transurethral microwave thermotherapy

Indexed keywords

CLINICAL PRACTICE; CLINICAL TRIAL; DEVICE; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; HUMAN; MALE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SAFETY; TRANSURETHRAL MICROWAVE THERMOTHERAPY;

EVIDENCE-BASED MEDICINE; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; TRANSURETHRAL RESECTION OF PROSTATE;

EID: 33845385628     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e3280104330     Document Type: Review

References (30)

1. Sackett DL, Rosenberg WMC, Muir Gray JA, et al. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312:71-72.
2. Guyatt GH, Haynes RB, Jaeschke RZ, et al. Users' Guides to the Medical Literature. XXV. Evidence-based medicine: principles for applying the Users' Guides to patient care. Evidence-Based Medicine Working Group. JAMA 2000; 284:1290-1296.
3. Bandolier Professional. On quality and validity. Available at http:// www.msdforphysicians.co.uk/bandolier/qvs.pdf. [Accessed 26 June 2006]
4. Lohr KN, Field MJ. A provisional instrument for assessing clinical practice guidelines. In: Field MJ, Lohr KN, editors. Guidelines for clinical practice. From development to use. Washington DC: National Academy Press; 1992. pp. 346-410.
5. Hoffman RM, McDonald R, Monga M, Wilt TJ. Transurethral microwave thermotherapy vs. transurethral resection for treating benign prostatic hyperplasic: a systematic review. BJU Int 2004; 94:1031-1036.
6. Gravas S, Laguna P, Ehrnebo M, et al. Seeking evidence that cell kill guided thermotherapy gives results not inferior to those of transurethral prostate resection: results of a pooled analysis of 3 studies of feedback transurethral microwave thermotherapy. J Urol 2005; 174:1002-1006. A pooled analysis of three studies of ProstaLund Feedback TUMT with 12-month follow-up.
7. Evans CP. Evidence-based medicine for the urologist. BJU Int 2004; 94:1-5.
8. Tan AH, Nott L, Hardie WR, et al. Long-term results of microwave thermotherapy for symptomatic benign prostatic hyperplasia. J Endourol 2005; 19:1191-1195.
9. Vesely S, Knutson T, Dicuio M, et al. Transurethral microwave thermotherapy: clinical results after 11 years of use. J Endourol 2005; 19:730-733.
10. Larson B, Huidobro C, Acevedo C, et al. In vivo temperature mapping of prostate during treatment with TherMatrx TMx-2000 device: heat field and MRI determinations of necrotic lesions. J Endourol 2005; 19:1021-1025. Assessment of thermal damage to prostate and prostatic urethra using TherMatrx TMx-2000 device.
11. de la Rosette J, Alivizatos G, Madersbacher S, et al. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001; 40:256-263.
12. AUA Practice Guideline Committee. AUA Guidelines on management of benign prostatic hyperplasia. Chapter 1. Diagnosis and treatment recommendations. J Urol 2003; 170:530-547.
13. Baba S, Badlani G, Elhilali M, et al. New minimally invasive and surgical developments in the management of BPO. In: Mc Connell J, Abrams P, Akaza H, Roerborn C, editors. 6th International Consultation on Prostate Cancer and Prostate Diseases. Paris, France: 2006. The most recent international guidelines on BPH that summarize the best available proofs and grade each recommendation based on the level of evidence.
14. de la Rosette JJMCH, Gravas S, Muschter R, et al. Present practice and development of minimally invasive techniques, imaging and training in European urology: results of a survey of the European Society of Uro-Technology (ESUT). Eur Urol 2003; 44:346-351.
15. Seki N, Naito S, Oshima S, et al. Prevalence and preference with regard to various surgical treatments for benign prostatic hypertrophy: a survey for the Japanese endourology and ESWL society member. Nippon Hinyokika Gakkai Zasshi 2003; 94:495-502.
16. Ercole B, Lee C, Best C, et al. Minimally invasive therapy for benign prostatic hyperplasia: practice patterns in Minnesota. J Endourol 2005; 19:159-162. An interesting study that illustrates the current situation in minimally invasive treatments for BPO.
17. Greving JP, Denig P, de Zeeuw D, Haaijer-Ruskamp FM. Physicians' attitudes towards treatment guidelines: differences between teaching and nonteaching hospitals. Eur J Clin Pharmacol 2006; 62:129-133. This study focuses on attitudes of clinicians regarding the content and usefulness of the guidelines.
18. Dahm P. Evidence-based medicine in prostate cancer: where do we stand today? Curr Opin Urol 2006; 16:162-167. A review of currently available evidence-based practice guidelines for newly diagnosed prostate cancer.
19. Evans CP. Evidence-based medicine for the urologist. BJU Int 2004; 94:1-5.
20. lrani J. Clinical Practice Guidelines (CPG): are they useful? Example of the benign prostatic hyperplasia (BPH). Ann Urol 2004; 38:S19-S23.
21. Stapleton AM, Cuncins-Hearn A, Pinnock C. Attitudes to evidence-based practice in urology: results of a survey. ANZ J Surg 2001; 71:297-300.
22. Emberton M. Clinical Practice Guidelines for the surgeon: how should they be understood and applied? BJU Int 2001; 88:485-492.
23. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America Project: benign prostatic hyperplasia. J Urol 2005; 173:1256-1261. An important review that presents data from BPH project in America with an emphasis on health resource use trends between 1990 and 2000.
24. Wilson JR, Urwin GH, Stower MJ. The changing practice of transurethral prostatectomy: a comparison of cases performed in 1990 and 2000. Ann R Coll Surg Engl 2004; 86:428-431.
25. Foley CL, Taylor C, Kirby RS. Counting the cost of treating benign prostatic hyperplasia. BJU Int 2004; 93:250-252.
26. Lotan Y, Cadeddu JA, Roehrborn CG, Stage KH. The value of your time: evaluation of effects of changes in Medicare reimbursement rates on the practice of urology. J Urol 2004; 172:1958-1962.
27. Disantostefano RL, Biddle AK, Lavelle JP. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia. BJU Int 2006; 97:1007-1016. An interesting study that estimates the costs and patient-related consequences of treatment alternatives for BPH over 20 years.
28. Vela-Navarette R, Gonzalez-Enguita G, Garcia-Gardoso JV, et al. The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade. BJU Int 2005; 96:1045-1048. This study highlights the differences in the clinical profile of patients undergoing surgery for BPH between 1992 and 2002.
29. d' Ancona FCH, van der Bij AK, Francisca EAE, et al. The results of high-energy transurethral microwave thermotherapy in patients categorized according to the American Society of Anaesthiologists operative risk classification (ASA). Urology 1999; 54:18-22.
30. de la Rosette J, Alivizatos G. Lasers for the treatment of bladder outlet obstruction: are they challenging conventional treatment modalities? [editorial]. Eur Urol 2006; 50:418-420.